A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCIDavid Adlam, Keith M. Channon, Maciej Zarębiński et al.|International Journal of Cardiology|2021Cited by 16
Role of interatrial conduction in atrial fibrillation: Mechanistic insights from renewal theory–based fibrillatory dynamic analysisJing Quah, Anand N. Ganesan, Matthew Tung et al.|Heart Rhythm O2|2022Cited by 4
A Randomised, Double-Blind, Dose Ranging Clinical Trial of Intravenous FDY-5301 in Acute STEMI Patients Undergoing Primary PCI: The CAMPFIRE (CArdiac Muscle Preservation Following Ischemia REperfusion) StudyDavid Adlam, CCC-ACS Investigators, N. Uren et al.|Circulation|2019Cited by 1
Clinical Trial Design of AT-02 Phase 2 Open Label Extension Study in Systemic Amyloidosis PC143 (#519)Spencer Guthrie, Matthew Meldorf, Marianna Fontana et al.|Unknown|2024Cited by 0